Anna Mowry - 29 May 2025 Form 4 Insider Report for Nautilus Biotechnology, Inc. (NAUT)

Role: CFO and Treasurer
Signature: /s/ Mathew B. Murphy, as Attorney-in-Fact
Issuer symbol: NAUT
Transactions as of: 29 May 2025
Net transactions value: +$11,488
Form type: 4
Filing time: 02 Jun 2025, 17:12:33 UTC
Previous filing: 04 Mar 2025
Next filing: 04 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Mowry Anna	CFO and Treasurer	C/O NAUTILUS BIOTECHNOLOGY, INC., 2701 EASTLAKE AVENUE EAST, SEATTLE	/s/ Mathew B. Murphy, as Attorney-in-Fact	02 Jun 2025	0001856938

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NAUT	Common Stock	Purchase	$11,488	+15,000	+22%	$0.7659	83,000	29 May 2025	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the weighted average share price of an aggregate total of 15,000 shares purchased in the price range of $0.7662 to $0.7489 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
F2	Includes the following shares of Common Stock acquired through the Issuer's 2021 Employee Stock Purchase Plan: (i) 1,250 shares on December 1, 2022; (ii) 1,250 shares on June 1, 2023; (iii) 1,250 shares on December 1, 2023; (iv) 2,500 shares on May 31, 2024; (v) 2,500 shares on November 29, 2024; and (vi) 2,500 shares on May 30, 2025.